89 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
, compared to $13.2 million for 2022. The increase was primarily related to higher employee compensation and benefits driven by increased headcount
8-K
EX-1.1
CGTX
Cognition Therapeutics Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
due to “stay at home”, “shelter-in-place”, “non-essential employee” or any other similar orders or restrictions or the closure of any physical branch … or directors of the Company pursuant to any stock or option plan duly adopted for such purpose by a majority of the non-employee members of the Board
424B5
te0ia
13 Mar 24
Prospectus supplement for primary offering
4:04pm
424B5
voyh9l9d
11 Mar 24
Prospectus supplement for primary offering
4:06pm
424B4
o1crevn 9ored
8 Jan 24
Prospectus supplement with pricing info
4:11pm
8-K
EX-10.1
zszvx46gv7t4
1 May 23
Departure of Directors or Certain Officers
7:30am
8-K
EX-10.1
ndfmnl78xsvgn
23 Dec 22
Entry into a Material Definitive Agreement
4:24pm
S-3
EX-4.4
5rwv6ioy
23 Dec 22
Shelf registration
4:16pm
S-3
qhevo4so8 y5jc1
23 Dec 22
Shelf registration
4:16pm
S-3
EX-1.2
8qdv6jbacij89h q6p
23 Dec 22
Shelf registration
4:16pm